These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 16820893)
1. Opioid growth factor receptor is unaltered with the progression of human pancreatic and colon cancers. Zagon IS; McLaughlin PJ Int J Oncol; 2006 Aug; 29(2):489-94. PubMed ID: 16820893 [TBL] [Abstract][Full Text] [Related]
2. Progression of squamous cell carcinoma of the head and neck is associated with down-regulation of the opioid growth factor receptor. McLaughlin PJ; Zagon IS Int J Oncol; 2006 Jun; 28(6):1577-83. PubMed ID: 16685459 [TBL] [Abstract][Full Text] [Related]
3. Overexpression of the opioid growth factor receptor downregulates cell proliferation of human squamous carcinoma cells of the head and neck. McLaughlin PJ; Verderame MF; Hankins JL; Zagon IS Int J Mol Med; 2007 Mar; 19(3):421-8. PubMed ID: 17273790 [TBL] [Abstract][Full Text] [Related]
4. Defects in the opioid growth factor receptor in human squamous cell carcinoma of the head and neck. McLaughlin PJ; Stack BC; Levin RJ; Fedok F; Zagon IS Cancer; 2003 Apr; 97(7):1701-10. PubMed ID: 12655527 [TBL] [Abstract][Full Text] [Related]
5. Opioid growth factor (OGF) inhibits anchorage-independent growth in human cancer cells. Zagon IS; McLaughlin PJ Int J Oncol; 2004 Jun; 24(6):1443-8. PubMed ID: 15138586 [TBL] [Abstract][Full Text] [Related]
6. Opioid growth factor inhibition of a human squamous cell carcinoma of the head and neck in nude mice: dependency on the route of administration. McLaughlin PJ; Stack BC; Braine KM; Ruda JD; Zagon IS Int J Oncol; 2004 Jan; 24(1):227-32. PubMed ID: 14654962 [TBL] [Abstract][Full Text] [Related]
7. Prevention and delay in progression of human squamous cell carcinoma of the head and neck in nude mice by stable overexpression of the opioid growth factor receptor. McLaughlin PJ; Kreiner S; Morgan CR; Zagon IS Int J Oncol; 2008 Oct; 33(4):751-7. PubMed ID: 18813788 [TBL] [Abstract][Full Text] [Related]
8. Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck. Jaglowski JR; Zagon IS; Stack BC; Verderame MF; Leure-duPree AE; Manning JD; McLaughlin PJ Cancer Chemother Pharmacol; 2005 Jul; 56(1):97-104. PubMed ID: 15791460 [TBL] [Abstract][Full Text] [Related]
9. Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells. Zagon IS; Verderame MF; Hankins J; McLaughlin PJ Int J Oncol; 2007 Apr; 30(4):775-83. PubMed ID: 17332915 [TBL] [Abstract][Full Text] [Related]
10. Prevention and delay in progression of human pancreatic cancer by stable overexpression of the opioid growth factor receptor. Zagon IS; Kreiner S; Heslop JJ; Conway AB; Morgan CR; McLaughlin PJ Int J Oncol; 2008 Aug; 33(2):317-23. PubMed ID: 18636152 [TBL] [Abstract][Full Text] [Related]
11. Regulation of cell proliferation by the opioid growth factor receptor is dependent on karyopherin beta and Ran for nucleocytoplasmic trafficking. Cheng F; McLaughlin PJ; Zagon IS Exp Biol Med (Maywood); 2010 Sep; 235(9):1093-101. PubMed ID: 20705629 [TBL] [Abstract][Full Text] [Related]
12. The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer. Cheng F; McLaughlin PJ; Verderame MF; Zagon IS Mol Cancer; 2008 Jan; 7():5. PubMed ID: 18190706 [TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of opioid growth factor receptor in human pancreatic adenocarcinoma. Zagon IS; Smith JP; Conter R; McLaughlin PJ Int J Mol Med; 2000 Jan; 5(1):77-84. PubMed ID: 10601579 [TBL] [Abstract][Full Text] [Related]
14. Opioid growth factor (OGF) inhibits the progression of human squamous cell carcinoma of the head and neck transplanted into nude mice. McLaughlin PJ; Levin RJ; Zagon IS Cancer Lett; 2003 Sep; 199(2):209-17. PubMed ID: 12969794 [TBL] [Abstract][Full Text] [Related]
15. B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases. Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ Immunobiology; 2011; 216(1-2):173-83. PubMed ID: 20598772 [TBL] [Abstract][Full Text] [Related]
16. The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer. Cheng F; Zagon IS; Verderame MF; McLaughlin PJ Cancer Res; 2007 Nov; 67(21):10511-8. PubMed ID: 17974995 [TBL] [Abstract][Full Text] [Related]
17. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases. Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ Immunobiology; 2011 May; 216(5):579-90. PubMed ID: 20965606 [TBL] [Abstract][Full Text] [Related]
18. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice. Donahue RN; McLaughlin PJ; Zagon IS Gynecol Oncol; 2011 Aug; 122(2):382-8. PubMed ID: 21531450 [TBL] [Abstract][Full Text] [Related]
19. Under-expression of the opioid growth factor receptor promotes progression of human ovarian cancer. Donahue RN; McLaughlin PJ; Zagon IS Exp Biol Med (Maywood); 2012 Feb; 237(2):167-77. PubMed ID: 22328595 [TBL] [Abstract][Full Text] [Related]